NCT05666518 - A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions | Biotech Hunter

Enrollment

1,400

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Chronic Heart Failure

Interventions

DRUG

Vericiguat (Verquvo, BAY1021189)

Dosage at the discretion of the treating physician, based on the recommendations written in the product information.

DRUG

Standard of care

Dosage at the discretion of the treating physician

Trial Locations (1)

RECRUITING

Japanese registries, Multiple Locations